T-cell Responses to HPV16 in Women with Cervical Neoplasia
Author Information
Author(s): Steele J C, Mann C H, Rookes S, Rollason T, Murphy D, Freeth M G, Gallimore P H, Roberts S
Primary Institution: Cancer Research UK Institute for Cancer Studies, University of Birmingham
Hypothesis
How do HPV-specific T-cell responses vary among women with different grades of cervical neoplasia?
Conclusion
The study reveals that the HPV-specific CD4+ T-cell response is crucial for immunotherapy design targeting preinvasive disease.
Supporting Evidence
- T-cell responses were observed in 78% of samples.
- CD4+ responders were less frequent among those with progressive disease.
- 80% of cervical cancer patients demonstrated T-cell responses.
Takeaway
This study looked at how the immune system responds to a virus that can cause cervical cancer, finding that certain immune cells are important for fighting the virus.
Methodology
The study used ELISPOT assays to measure T-cell responses to five HPV16 proteins in women with varying grades of cervical disease.
Limitations
The HPV genotype of patient biopsies could not be established, and the study's findings may not be generalizable due to the specific patient cohort.
Participant Demographics
41 women attending colposcopy clinics or undergoing surgery for cervical disease, including a control group of 9 age-matched female virgins.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website